JP2019514367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514367A5 JP2019514367A5 JP2018555114A JP2018555114A JP2019514367A5 JP 2019514367 A5 JP2019514367 A5 JP 2019514367A5 JP 2018555114 A JP2018555114 A JP 2018555114A JP 2018555114 A JP2018555114 A JP 2018555114A JP 2019514367 A5 JP2019514367 A5 JP 2019514367A5
- Authority
- JP
- Japan
- Prior art keywords
- imp
- protein
- eev
- fragment
- vaccinia virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000018697 Membrane Proteins Human genes 0.000 claims 29
- 108010052285 Membrane Proteins Proteins 0.000 claims 29
- 239000012634 fragment Substances 0.000 claims 23
- 108020001507 fusion proteins Proteins 0.000 claims 16
- 102000037865 fusion proteins Human genes 0.000 claims 16
- 241000700618 Vaccinia virus Species 0.000 claims 14
- 102000040430 polynucleotide Human genes 0.000 claims 14
- 108091033319 polynucleotide Proteins 0.000 claims 14
- 239000002157 polynucleotide Substances 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 150000007523 nucleic acids Chemical group 0.000 claims 13
- 239000012528 membrane Substances 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 6
- 239000007787 solid Substances 0.000 claims 6
- 101150073066 F13L gene Proteins 0.000 claims 5
- 102220465562 Putative uncharacterized protein OBSCN-AS1_F13L_mutation Human genes 0.000 claims 5
- 101100502046 Vaccinia virus (strain Western Reserve) VACWR052 gene Proteins 0.000 claims 5
- 101100502047 Variola virus (isolate Human/India/Ind3/1967) C17L gene Proteins 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 4
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000035085 multipass transmembrane proteins Human genes 0.000 claims 3
- 108091005494 multipass transmembrane proteins Proteins 0.000 claims 3
- 102220477045 Dynein axonemal assembly factor 10_A56R_mutation Human genes 0.000 claims 2
- 101150039660 HA gene Proteins 0.000 claims 2
- 108010090804 Streptavidin Proteins 0.000 claims 2
- 108700029871 Vaccinia virus 42kDa Proteins 0.000 claims 2
- 239000011324 bead Substances 0.000 claims 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 2
- 210000002845 virion Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101150115056 A31R gene Proteins 0.000 claims 1
- 101150108168 A33R gene Proteins 0.000 claims 1
- 101150049392 A34R gene Proteins 0.000 claims 1
- 101150076005 A36R gene Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 102100039820 Frizzled-4 Human genes 0.000 claims 1
- 102220603448 Homeobox protein SIX3_A34R_mutation Human genes 0.000 claims 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 1
- 101000885581 Homo sapiens Frizzled-4 Proteins 0.000 claims 1
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 claims 1
- 101710116435 Outer membrane protein Proteins 0.000 claims 1
- 101100000228 Vaccinia virus (strain Western Reserve) VACWR157 gene Proteins 0.000 claims 1
- 101100000236 Vaccinia virus (strain Western Reserve) VACWR159 gene Proteins 0.000 claims 1
- 101900242771 Vaccinia virus Protein A33 Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 102000052343 human FZD4 Human genes 0.000 claims 1
- 102000035160 transmembrane proteins Human genes 0.000 claims 1
- 108091005703 transmembrane proteins Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022077485A JP2022116013A (ja) | 2016-04-22 | 2022-05-10 | ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326501P | 2016-04-22 | 2016-04-22 | |
| US62/326,501 | 2016-04-22 | ||
| PCT/US2017/028787 WO2017184951A1 (en) | 2016-04-22 | 2017-04-21 | Integral membrane protein display on poxvirus extracellular enveloped virions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022077485A Division JP2022116013A (ja) | 2016-04-22 | 2022-05-10 | ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514367A JP2019514367A (ja) | 2019-06-06 |
| JP2019514367A5 true JP2019514367A5 (enExample) | 2020-05-28 |
| JP7072521B2 JP7072521B2 (ja) | 2022-05-20 |
Family
ID=60116403
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555114A Active JP7072521B2 (ja) | 2016-04-22 | 2017-04-21 | ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示 |
| JP2022077485A Pending JP2022116013A (ja) | 2016-04-22 | 2022-05-10 | ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022077485A Pending JP2022116013A (ja) | 2016-04-22 | 2022-05-10 | ポックスウイルス細胞外エンベロープビリオン上での膜内在性タンパク質の提示 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10577427B2 (enExample) |
| EP (2) | EP3445397B1 (enExample) |
| JP (2) | JP7072521B2 (enExample) |
| KR (1) | KR102558637B1 (enExample) |
| CN (2) | CN116286909A (enExample) |
| AU (1) | AU2017252427B2 (enExample) |
| BR (1) | BR112018071686A2 (enExample) |
| CA (1) | CA3018990A1 (enExample) |
| DK (1) | DK3445397T3 (enExample) |
| ES (1) | ES2935585T3 (enExample) |
| FI (1) | FI3445397T3 (enExample) |
| IL (1) | IL262232B2 (enExample) |
| MX (2) | MX388030B (enExample) |
| NZ (1) | NZ786461A (enExample) |
| PL (1) | PL3445397T3 (enExample) |
| PT (1) | PT3445397T (enExample) |
| RU (1) | RU2759846C2 (enExample) |
| SG (1) | SG11201808554TA (enExample) |
| WO (1) | WO2017184951A1 (enExample) |
| ZA (1) | ZA201806449B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2760890C (en) | 2009-05-08 | 2019-08-20 | Vaccinex, Inc. | Anti-cd100 antibodies and methods for using the same |
| PT2766093T (pt) | 2011-10-11 | 2018-05-18 | Vaccinex Inc | Utilização de moléculas de ligação a semaforina-4d para modulação da permeabilidade da barreira hematoencefálica |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| NZ631015A (en) | 2013-06-25 | 2019-08-30 | Vaccinex Inc | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| CA3032512C (en) | 2016-08-02 | 2025-05-06 | Vaccinex, Inc. | IMPROVED PROCESSES FOR PRODUCING POLYNUCLEOTIDE LIBRARIES IN VACCINE VIRUS/EUKARYOTIC CELLS |
| CN109706177A (zh) * | 2019-01-24 | 2019-05-03 | 浙江省医学科学院 | 一种重组痘苗病毒表面展示系统载体质粒及应用 |
| CA3156346A1 (en) * | 2019-10-02 | 2021-04-08 | Bionoxx Inc. | PROTEIN TARGETING A TUMOR OR ASSOCIATED FRAGMENT, ANTIBODY BINDING THEREOF AND USE THEREOF |
| IL297578A (en) | 2020-05-06 | 2022-12-01 | Vaccinex Inc | Integral membrane protein display on extracellular enveloped poxviruses |
| JP2023533813A (ja) * | 2020-07-14 | 2023-08-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 一定用量配合剤のアッセイ |
| CN116710476A (zh) * | 2020-07-14 | 2023-09-05 | 豪夫迈·罗氏有限公司 | 用于固定剂量组合的测定 |
| KR102419397B1 (ko) * | 2021-04-02 | 2022-07-14 | 주식회사 바이오녹스 | 항암바이러스 유래 단백질을 표적으로 하는 키메라 항원 수용체, 이를 발현하는 면역세포 및 이들의 용도 |
| KR102739298B1 (ko) * | 2021-04-02 | 2024-12-06 | 주식회사 바이오녹스 | 바이러스 벡터 유래 항암요법 표적 단백질 및 이에 특이적으로 결합하는 결합 분자 또는 이의 단편 |
| EP4536698A1 (en) | 2022-06-10 | 2025-04-16 | Vaccinex, Inc. | Methods to select antibodies specific to complex membrane antigens |
| JP2025540894A (ja) * | 2022-11-29 | 2025-12-16 | マルコープ・バイオディスカバリーズ・リミテッド | 新規ｃｄ２０タンパク質 |
| CN116218879B (zh) * | 2022-12-28 | 2025-09-09 | 中国人民解放军军事科学院军事医学研究院 | 一种单价广谱的正痘病毒属mRNA疫苗及其应用 |
| WO2025184411A1 (en) | 2024-02-27 | 2025-09-04 | Calidi Biotherapeutics (Nevada), Inc. | Serum-resistant eev viruses and uses thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US6218525B1 (en) * | 1988-02-25 | 2001-04-17 | The General Hospital Corporation | Nucleic acid encoding CD28 |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| EP0897980A3 (en) * | 1997-08-20 | 2002-04-17 | Smithkline Beecham Corporation | CXCR4B: A human splice variant of CXCR4 chemokine receptor |
| EP1137769B1 (en) | 1998-11-10 | 2008-09-03 | University Of Rochester | Methods for the generation of dna libraries |
| US7198920B1 (en) * | 1999-01-29 | 2007-04-03 | Corika Corporation | HER-2/neu fusion proteins |
| WO2001002551A2 (en) | 1999-06-30 | 2001-01-11 | Evotec Oai Ag | Virus like particles, preparation and use in screening and functional genomics |
| US20040014033A1 (en) * | 1999-06-30 | 2004-01-22 | Evotec Biosystems Ag, A Corporation Of Germany | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics |
| DE60126130T2 (de) | 2000-11-17 | 2007-10-18 | The University Of Rochester | In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen |
| US7645456B2 (en) | 2001-04-23 | 2010-01-12 | Sanofi Pasteur Biologics Co. | Vaccinia virus strains |
| US20030044409A1 (en) | 2001-05-01 | 2003-03-06 | Carson Dennis A. | Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens |
| US7244592B2 (en) * | 2002-03-07 | 2007-07-17 | Dyax Corp. | Ligand screening and discovery |
| CA2431349A1 (en) | 2002-06-06 | 2003-12-06 | Xiao-Dan Yao | Method of producing a recombinant virus |
| US20060003316A1 (en) * | 2002-07-15 | 2006-01-05 | John Simard | Immunogenic compositions derived from poxviruses and methods of using same |
| US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| CA2503390A1 (en) * | 2002-11-01 | 2004-05-21 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| US20050158323A1 (en) | 2003-12-04 | 2005-07-21 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| US8022043B2 (en) | 2004-08-27 | 2011-09-20 | Albert Einstein College Of Medicine Of Yeshiva University | Ceramide derivatives as modulators of immunity and autoimmunity |
| US7772380B2 (en) | 2004-08-27 | 2010-08-10 | Albert Einstein College Of Medicine Of Yeshiva University | Ceramide derivatives as modulators of immunity and autoimmunity |
| CN101128586A (zh) * | 2004-12-22 | 2008-02-20 | 健泰科生物技术公司 | 制备可溶性多跨膜蛋白的方法 |
| US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| WO2008100995A1 (en) | 2007-02-14 | 2008-08-21 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
| AU2008219020B2 (en) | 2007-02-21 | 2013-08-22 | Vaccinex, Inc. | Modulation of NKT cell activity with antigen-loaded CDId molecules |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| US8637026B2 (en) | 2007-12-26 | 2014-01-28 | Vaccinex, Inc. | Anti-C35 antibody combination therapies and methods |
| KR101708277B1 (ko) * | 2008-05-28 | 2017-02-20 | 이노비오 파마수티컬즈, 인크. | 천연두 ｄｎａ 백신 및 면역 반응을 유도하는 상기 백신 내에 항원 |
| CA2748819A1 (en) | 2009-01-08 | 2010-07-15 | Steven A. Porcelli | Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof |
| CA2760890C (en) | 2009-05-08 | 2019-08-20 | Vaccinex, Inc. | Anti-cd100 antibodies and methods for using the same |
| CA2802376A1 (en) | 2010-06-14 | 2011-12-22 | Vaccinex, Inc. | Anti-vegf antibodies and uses thereof |
| CA2804029A1 (en) | 2010-07-07 | 2012-01-12 | Steven A. Porcelli | Ceramide-like glycolipid-associated bacterial vaccines and uses thereof |
| BR112013005145B1 (pt) | 2010-09-02 | 2022-02-15 | Vaccinex, Inc | Anticorpo isolado ou seu fragmento de ligação ao antígeno que se liga especificamente ao cxcl13, composição e uso de uma composição |
| KR102003571B1 (ko) | 2011-05-13 | 2019-07-24 | 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 | 골형성 촉진제 |
| PT2766093T (pt) | 2011-10-11 | 2018-05-18 | Vaccinex Inc | Utilização de moléculas de ligação a semaforina-4d para modulação da permeabilidade da barreira hematoencefálica |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| CA2865928C (en) | 2012-03-02 | 2021-02-16 | Vaccinex, Inc. | Cxcl13 antagonist for the treatment of sjogren's syndrome |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) * | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| KR102176962B1 (ko) | 2013-01-31 | 2020-11-10 | 백시넥스 인코포레이티드 | 면역글로불린 a 수준을 증가시키기 위한 방법 |
| US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
| NZ631015A (en) | 2013-06-25 | 2019-08-30 | Vaccinex Inc | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| DK3158058T3 (da) * | 2014-06-18 | 2019-07-01 | Morphosys Ag | Fusionsproteiner og bruger deraf |
| CA3032512C (en) | 2016-08-02 | 2025-05-06 | Vaccinex, Inc. | IMPROVED PROCESSES FOR PRODUCING POLYNUCLEOTIDE LIBRARIES IN VACCINE VIRUS/EUKARYOTIC CELLS |
| US20190383836A1 (en) | 2017-02-22 | 2019-12-19 | Vaccinex, Inc. | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
| PL3600419T3 (pl) | 2017-03-20 | 2024-02-19 | Vaccinex, Inc. | Leczenie raka przeciwciałem wiążącym semaforynę-4d w kombinacji ze środkiem epigenetycznie modulującym |
| AU2018261947B2 (en) | 2017-05-05 | 2024-06-13 | Vaccinex, Inc. | Human anti-semaphorin 4D antibody |
-
2017
- 2017-04-21 BR BR112018071686-3A patent/BR112018071686A2/pt active Search and Examination
- 2017-04-21 FI FIEP17786694.4T patent/FI3445397T3/fi active
- 2017-04-21 MX MX2018012818A patent/MX388030B/es unknown
- 2017-04-21 AU AU2017252427A patent/AU2017252427B2/en active Active
- 2017-04-21 CA CA3018990A patent/CA3018990A1/en active Pending
- 2017-04-21 KR KR1020187033790A patent/KR102558637B1/ko active Active
- 2017-04-21 JP JP2018555114A patent/JP7072521B2/ja active Active
- 2017-04-21 CN CN202211138346.9A patent/CN116286909A/zh active Pending
- 2017-04-21 CN CN201780025118.1A patent/CN109069613B/zh active Active
- 2017-04-21 US US16/091,077 patent/US10577427B2/en active Active
- 2017-04-21 PL PL17786694.4T patent/PL3445397T3/pl unknown
- 2017-04-21 IL IL262232A patent/IL262232B2/en unknown
- 2017-04-21 ES ES17786694T patent/ES2935585T3/es active Active
- 2017-04-21 EP EP17786694.4A patent/EP3445397B1/en active Active
- 2017-04-21 NZ NZ786461A patent/NZ786461A/en unknown
- 2017-04-21 SG SG11201808554TA patent/SG11201808554TA/en unknown
- 2017-04-21 DK DK17786694.4T patent/DK3445397T3/da active
- 2017-04-21 EP EP22165288.6A patent/EP4059516A1/en active Pending
- 2017-04-21 RU RU2018140971A patent/RU2759846C2/ru active
- 2017-04-21 WO PCT/US2017/028787 patent/WO2017184951A1/en not_active Ceased
- 2017-04-21 PT PT177866944T patent/PT3445397T/pt unknown
-
2018
- 2018-09-27 ZA ZA2018/06449A patent/ZA201806449B/en unknown
- 2018-10-19 MX MX2021013783A patent/MX2021013783A/es unknown
-
2019
- 2019-04-15 US US16/384,087 patent/US10550199B2/en active Active
- 2019-12-26 US US16/727,151 patent/US10870707B2/en active Active
-
2022
- 2022-05-10 JP JP2022077485A patent/JP2022116013A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514367A5 (enExample) | ||
| RU2018140971A (ru) | Дисплей интерального мембранного белка на внеклеточных оболочечных вирионах поксвируса | |
| Melero et al. | Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development | |
| JP2015212284A5 (enExample) | ||
| JP2019033754A5 (enExample) | ||
| WO2024109611A1 (zh) | 突变型呼吸道合胞病毒融合前f蛋白及其应用 | |
| JP2005120106A5 (enExample) | ||
| JP2014533518A5 (enExample) | ||
| HUP0002070A2 (hu) | Alternatív módon célba juttatott adenovírus | |
| JP2007535912A5 (enExample) | ||
| JP2015514811A5 (enExample) | ||
| JP2017514522A5 (enExample) | ||
| JP2014503198A5 (enExample) | ||
| JP2013517783A5 (enExample) | ||
| JP2008524261A5 (enExample) | ||
| JP2018504911A5 (enExample) | ||
| JP2016508143A5 (enExample) | ||
| Masuda et al. | Stable trimer formation of spike protein from porcine epidemic diarrhea virus improves the efficiency of secretory production in silkworms and induces neutralizing antibodies in mice | |
| JP2019511457A5 (enExample) | ||
| CN104845981B (zh) | 田鼠巴贝虫Bm1524抗原及其应用 | |
| CN116143888A (zh) | 非洲猪瘟病毒p30蛋白抗原表位多肽及其应用 | |
| CN115368443A (zh) | 非洲猪瘟病毒CD2v蛋白B细胞线性表位及应用 | |
| RU2017145246A (ru) | Рекомбинантный белок, содержащих антигенно-значимые фрагменты белков вируса гепатита Е, используемый в тест-системах для серодиагностики гепатита Е (ВАРИАНТЫ) | |
| NZ746657B2 (en) | Integral membrane protein display on poxvirus extracellular enveloped virions | |
| NZ794089B2 (en) | Integral membrane protein display on poxvirus extracellular enveloped virions |